Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Page 1
BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P, Gunz G, Saveanu A, Barlier A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Culler MD. Jaquet P, et al. Among authors: gunz g. J Endocrinol Invest. 2005;28(11 Suppl International):21-7. J Endocrinol Invest. 2005. PMID: 16625841
We report the comparative efficacy of a somatostatin receptor 1 and 5 subtypes (SSTR2 and SSTR5), and dopamine D2 (DAD2) compound, BIM-23A760, in suppressing GH secretion, in cell culture from human GH-secreting tumors, from patients partially responsive to long-term treat …
We report the comparative efficacy of a somatostatin receptor 1 and 5 subtypes (SSTR2 and SSTR5), and dopamine D2 (DAD2) compound, BIM-23A76 …
A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies.
Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. Saveanu A, et al. Among authors: gunz g. Eur J Endocrinol. 2001 Jul;145(1):35-41. doi: 10.1530/eje.0.1450035. Eur J Endocrinol. 2001. PMID: 11415850
The endocrine evaluation showed high plasma levels of PRL, LH, and alpha-subunit inhibited by 65%, 65% and 33% respectively under octreotide test (200 microg, s.c.). Long-term treatment with slow release (SR) lanreotide (30 mg/10 days, i.m.) restored menstrual cycles and n …
The endocrine evaluation showed high plasma levels of PRL, LH, and alpha-subunit inhibited by 65%, 65% and 33% respectively under octreotide …
Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas.
Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Barlier A, et al. Among authors: gunz g. J Clin Endocrinol Metab. 1998 May;83(5):1604-10. doi: 10.1210/jcem.83.5.4797. J Clin Endocrinol Metab. 1998. PMID: 9589663
A better octreotide sensitivity of mutated adenomas was clearly shown under in vivo (short and long term) and in vitro conditions. During the acute octreotide test, the GH nadir was significantly lower in the gsp-positive adenomas (85% of maximal inhibition vs. 52%). ...
A better octreotide sensitivity of mutated adenomas was clearly shown under in vivo (short and long term) and in vitro conditions. Du …
In vitro corticotropin-releasing hormone (CRH) stimulation of adrenocorticotropin release from corticotroph adenoma cells: effect of prolonged exposure to CRH and its interaction with cortisol.
Grino M, Boudouresque F, Conte-Devolx B, Gunz G, Grisoli F, Oliver C, Jaquet P. Grino M, et al. Among authors: gunz g. J Clin Endocrinol Metab. 1988 Apr;66(4):770-5. doi: 10.1210/jcem-66-4-770. J Clin Endocrinol Metab. 1988. PMID: 2831247
A 4-day incubation with cortisol induced a dose-dependent decrease in both basal and long term CRH-stimulated ACTH release, with no difference in the IC50 (1 X 10(-8) mol/L). These data suggest that long term exposure to CRH does not desensitize corticotroph adenoma …
A 4-day incubation with cortisol induced a dose-dependent decrease in both basal and long term CRH-stimulated ACTH release, with no d …
Bromocriptine effects on cultured human prolactin-producing pituitary adenomas: in vitro ultrastructural, morphometric, and immunoelectron microscopic studies.
Hassoun J, Jaquet P, Devictor B, Andonian C, Grisoli F, Gunz G, Toga M. Hassoun J, et al. Among authors: gunz g. J Clin Endocrinol Metab. 1985 Oct;61(4):686-92. doi: 10.1210/jcem-61-4-686. J Clin Endocrinol Metab. 1985. PMID: 4031013
These results, obtained for the first time in human PRL-producing adenomas, are informative as to the subcellular events subsequent to short term BR treatment and illustrate that secretory inhibition and tumor shrinkage are not necessarily linked....
These results, obtained for the first time in human PRL-producing adenomas, are informative as to the subcellular events subsequent to short …